1993  1994  1995  1995  1995  1995  1995  1996  1996 1996 1996 1997 1997 1997 1998  July  June  March  August  October  November  November  January  March  June  September  February  April  August  January  September  December  Guilford Pharmaceuticals Inc.   Founded  Guilford completes IPO   Guilford completes manufacturing   facility for GLIADEL Wafer  Guilford completes $19.5 million public   offering of common stock  Guilford receives clearance for  GLIADEL Wafer Treatment IND   Guilford signs GLIADEL Wafer  collaboration with Orion-Farmos   Guilford announces GLIADEL Wafer   Phase III European trial results  Guilford announces corporate partnership   with Daiichi Radioisotopes Ltd. for  DOPASCAN Injection  Guilford completes $46 million public   offering of common stock  Guilford signs worldwide marketing   agreement for GLIADEL Wafer  with Rhône-Poulenc Rorer  (excludes Scandinavia and Japan)  Guilford receives FDA marketing   clearance for GLIADEL Wafer  Rhône-Poulenc Rorer launches  GLIADEL Wafer in the US  Guilford completes $75 million  public offering of common stock   Amgen enters into agreement with   Guilford for Neuroimmunophilin  Ligand Program  Multinational Phase III clinical trial   of GLIADEL Wafer begins for  newly diagnosed patients with  malignant glioma  Guilford selects lead NAALADase  inhibitor for clinical development   Guilford receives international health   authority approvals for GLIADEL  Wafer in Canada and France